Skip to main content

The inhibition of sorting proteins as a therapeutic avenue in HER2 positive breast cancer

Objective

HER2+ breast cancers are an aggressive type of breast cancer and have a poor prognosis. There are many therapies currently on the market to target this type of cancer, however they fail to deliver effective clinical results due to therapy resistance. In our ERC-CoG project, we found that proper endosomal trafficking is required for functional HER2 oncogenic signalling at the plasma membrane. Targeting HER2 endosomal traffic can result in effective treatment of HER2+ cancers, without the risk of therapy resistance. As such, this innovation could deliver the first truly effective cancer treatment for HER2+ breast cancer patients that do not respond to current treatments. In this ERC-PoC, we aim to prove that therapeutic targeting of endosomal traffic is effective in HER2+ cancer models in vivo, as a monotherapy and synergistically with current therapeutic antibodies, and to explore the commercial avenues to exploit this finding.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

ERC-2017-PoC
See other projects for this call

Funding Scheme

ERC-POC - Proof of Concept Grant

Host institution

TURUN YLIOPISTO
Address
Yliopistonmaki
20014 Turku
Finland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

TURUN YLIOPISTO
Finland
EU contribution
€ 150 000
Address
Yliopistonmaki
20014 Turku
Activity type
Higher or Secondary Education Establishments